FDA Foreign Trials Proposed Rule Would Mandate "Good Clinical Practices," Not Helsinki Declaration
This article was originally published in The Pink Sheet Daily
Executive Summary
The proposal for ex-U.S., non-IND studies would require human subject protections in line with ICH guidances. FDA has been concerned about the most recent revisions to the Declaration of Helsinki requiring comparator trials to be used instead of placebo-controlled studies whenever possible.